medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2008, Número 4

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2008; 55 (4)


Esteatosis hepática, esteatohepatitis y marcadores de lesión hepática

Barba EJR

Idioma: Español
Referencias bibliográficas: 60
Paginas: 216-232
Archivo PDF: 164.84 Kb.


RESUMEN

Enfermedad de hígado graso no alcohólica (EHGNA) afecta a una gran proporción de la población. Es una entidad clinicopatológica caracterizada por el desarrollo de cambios histológicos en el hígado que son muy idénticos a aquellos que son inducidos por el consumo excesivo de alcohol, pero en ausencia del consumo de éste. Obesidad, resistencia a la insulina, diabetes y estrés oxidativo juegan un papel importante en la patogénesis de esta enfermedad. La biopsia hepática permanece como el medio más sensible y específico que provee información pronóstica importante.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TIA, Becker U, Bendtsen F. Long term prognosis of fatty liver: Risk of chronic liver disease and death. Gut 2004; 53: 750-755.

  2. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114 (2): 147-152.

  3. Bayard M, Holt J, Boroughs E. Nonalcholic fatty liver disease. Am Fam Phys 2006; 73: 1961-1968.

  4. Chrobot A. Steatohepatitis, overweight, obesity in adolescents – civilization problem in next years? Prevalence of abnormal serum aminotransferase values – diagnostic problem. Case Rep Pract Rev 2001; 2 (4): 265-267.

  5. Cavanilles WE, Solar BA, García AL, Lorenzo PMJ. Eficacia de la reducción de peso en la curación de la esteatohepatitis no alcohólica en un adolescente obeso. An Pediatr 2007; 66 (2): 184-187.

  6. Poynard T, Ratziu V, Charlotte F, Messous D et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcohol steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 2006; 6 (34): 1-17.

  7. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346 (16): 1221-1231.

  8. Bellentani S, Saccoccio G, Masutti F, Croce L, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Am Coll Phys 2000; 132 (2): 112-117.

  9. Vilar JH. Esteatohepatitis no alcohólica. Rev Med Nordeste 2002; 2: 5-12.

  10. Silvestre V, Ruano M, García-Lescún MCG, Aguirregoicoa E, Criado L, Rodríguez A, Marco A, García-Blanch G. Obesidad morbosa, enfermedad de hígado graso no alcohólico, síndrome metabólico y cirugía bariátrica. Nutr Hosp 2007; 22 (5): 602-606.

  11. Moreno SD. Tratamiento médico de la hepatopatía grasa no alcohólica primaria. Med Clin (Barc) 2005; 125 (3): 108-116.

  12. The American Gastroenterological Association. AGA Technical Review on Nonalcoholic Fatty Liver Disease. Gastroenterology 2002; 123: 1705-1725.

  13. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357: 1069-1075.

  14. Rashid M, Roberts E. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterl Nutr 2000; 30 (1): 48-53.

  15. Bernal RR, Saenz-Labra A, Bernardo ER. Prevalencia de la esteatohepatitis no alcohólica (EHNA). Estudio comparativo con diabéticos. Rev Gastroenterol Mex 2000; 65 (2): 58-62.

  16. Fassio E, Álvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-826.

  17. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, de Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.

  18. Neuschwander TBA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.

  19. García MC. Controversias en esteatohepatitis no alcohólica. Gastroenterol Hepatol 2003; 26 (supl 2): 7-10.

  20. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous, Dominique CD, Abella A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Abrecht J. The diagnostic value of biomarkers (Steato Test) for the prediction of liver steatosis. Comp Hepatol 2005; Disponible en: http://www.comparative-hepatology.com/contest/4/1/10

  21. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-145.

  22. Adams LA, Lymp JF, Sauver JST, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005; 129: 113-121.

  23. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Capron D, Abella A, Muntean M. The diagnostic value of biomarkers (Steatotest) for the prediction of liver steatosis. Comp Hepatol 2005. Disponible en: http://www.comparative-hepatology.com/ contest/4/1/10.

  24. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353: 1634-1636.

  25. Lizardi CJ, Motola KD, Guevara GL. La obesidad y su asociación con el desarrollo de cirrosis criptogénica y hepatocarcinoma. Gac Med Mex 2004; 140 (supl 2): S77-S83.

  26. Day CP, Oliver FWJ. Hepatic steatosis: Innocent bystander or guilty party? Hepatology 1998; 27 (6): 1463-1466.

  27. Pérez-Carrera M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, Colina F, Arenas J, Solis-Herruzo JA. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999-1007.

  28. Margrethe V, Struben D, Erickson HE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000; 108: 9-13.

  29. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.

  30. Abdul M, Phaik-Leng C, Ida NH, Siew PC, Khean-Lee G. Non-alcoholic fatty liver disease in Malaysia: A demographic, anthropometric, metabolic and histological study. J Dig Dis 2007; 8; 58-64.

  31. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.

  32. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE. Histopathology of pediatrics nonalcoholic fatty liver disease. Hepatology 2005; 42: 641-649.

  33. Guzzaloni G, Grugni G, Minocci A, Moro D, Morabito F. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerant test. Internat J Obesity 2000; 24: 772-776.

  34. Clark JM, Diehl AM. Nonalcoholic fatty liver disease. An underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-3004.

  35. Suárez HME, Ruiz PM, Santana VC, Barrios GE. Obesidad infanto-juvenil: Diagnóstico, evaluación, seguimiento y criterios de derivación hospitalaria. Obesidad: Manejo en pediatría de atención primaria. BSCP Can Ped 2005; 29 (2): 111-118.

  36. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: A clinical histopathological study. Am J Gastroenterol 2003; 98 (9): 2042-2047.

  37. Jian-Meng L, Rongwei Y, Song L et al. Prevalence of overweight/obesity in Chinese children. Arc Med Res 2007; 38 (8): 882-886.

  38. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer J, Lavine J. Pediatric nonalcoholic fatty liver disease: A critical appraisal of current data and implications for future research. J Pediatr Gastroenterl Nutr 2006; 43 (4): 413-427.

  39. Castéra L, Verginol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, de Lédinghen V. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.

  40. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657.

  41. Kew MC. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 2000; 355: 591-592.

  42. Thabut D, Naveau S, Charlotte F, Massard J, Ratziu V, Imbert-Bismut F, Cazals-Hatem D, Abella A, Messous D, Beuzen F, Munteanu M, Taieb J, Moreau R, Lebrec R, Poynard T. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J Hepatol 2006; 44: 1175-1185.

  43. Munteanu M, Messous D, Thabut D, Imbert-Bismut F, Jouys M, Massard J, Piton A, Bonyhay L, Ratziu V, Hainque B, Poynard T. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest). Comp Hepatol 2004. Disponible en: http://www.comparative-hepatology.com/contest/3/1/3.

  44. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: A comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2419-2425.

  45. Hidekatsu Yanai. Diagnosis of nonalcoholic fatty liver disease. JAMA 2003; 290 (12): 1577.

  46. Poynard T, Bismut PI, Munteanu M, Messous D, Myers RP, Thabut D. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV Fibrosure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004. Disponible en: http://www.comparative-hepatology.com/contest/3/1/38.

  47. Rosenberg WMC, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJP. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004; 127: 1704-1713.

  48. Ratziu V, Giral P, Munteanu M, Messouss D, Mercadier A, Bernards M, Morra R, Imbert-Bismuts F, Bruckert E, Poynard T. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 2007; 25: 207-218.

  49. Poynard T, Imbert-Bismut F, Munteanum M, Ratziu V. Diagnosis and treatment of viral liver fibrosis. Saudi J Gastroenterol 2005; 11 (1): 1-19.

  50. Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J. Biomarkers as a first-line estimate of injury in chronic liver diseases: Time for a moratorium on liver biopsy? Gastroenterology 2005; 128 (4): 1146-1148.

  51. Pratt DS, Kaplan MM. Primary care: Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342 (17): 1266-1271.

  52. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: An agenda for clinical research. Hepatology 2002; 35 (4): 746-752.

  53. Solis HJA, Solis MP. Iron, hepatitis C virus and hepatic steatosis. Rev Esp Enferm Dig 2004; 96 (12): 809-817.

  54. American Gastroenterological Association. American Gastroenterological Association Medical Position Statement: Nonalcoholic Fatty Liver Disease. Gastroenterology 2002; 123: 1702-1704.

  55. Sorbi D, Boynton JJ, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94 (4): 1018-1022.

  56. Louthan MV, Theriot JA, Zimmerman E, Stutts JT, McClain CJ. Decreased prevalence of nonalcoholic fatty liver disease in black obese children. J Pediatr Gastroenterl Nutr 2005; 41: 426-429.

  57. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-1413.

  58. Hui AY, Wong VWS, Chan HLY, Liew CT, Chan JLY, Chan FKL, Sung JJY. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005; 21: 407-413.

  59. Sathya P, Martin S, Alvarez F. Nonalcoholic fatty liver disease (NAFLD) in children. Curr Nopinion Pediatr 2002; 14 (5): 593-600.

  60. Vajro P, Fontanella A, Perna C, Orso G, Tudesco M, De Vicenio A. Persistent hyperaminotransferasemia resolving alter weight reduction in obese children. J Pediatr 1994; 125: 239-241.




2020     |     www.medigraphic.com